Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Emerging infectious diseases (EIDs) are characterized by unpredictable incidence and clinical patterns that pose unique challenges for vaccine development. As outbreaks of Ebola virus, Zika virus, and other EIDs have occurred in the past decade, drug developers and global health organizations are turning to novel funding and clinical trial paradigms to improve epidemic preparedness. This report covers current and future challenges for the development and deployment of vaccines for EIDs, focusing on vaccine platform technology and research, funding mechanisms, and collaborative global partnerships.

Scope

GlobalData’s Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at vaccines for emerging infectious diseases in the US, Europe, Asia, and Africa.

Components of the report include:

• Overview of EIDs – Background, drivers of transmission, and overview of key EIDs.

• Clinical Trial Design – How vaccine for EIDs clinical trials are being designed and what regulatory strategies are being explored.

• Vaccine Platform Technologies – How the current platform technologies for vaccines compare.

• Pipeline Assessment for Key EIDs – What are the pipeline vaccine products in development for key EIDs.

• Funding and Market Incentives – How vaccine development is being incentivized in the public and private spaces.

• Global Collaborations – How global and public-private partnership organizations are supporting vaccine development.

• Vaccine Preparedness – The current and future challenges face vaccine preparedness from a surveillance and infrastructure perspective.

Reasons to Buy

Develop business strategies by understanding the global trends shaping and driving the vaccines for EIDs market

Formulate effective sales and marketing strategies by understanding the competitive landscape of various competitors in a niche therapeutic space.

Identify areas of unmet need within the vaccines for EIDs market to help drive research and development towards future market opportunities.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key funding and partnership strategies.

Bharat Biotech
Emergent Biosolution
IDT Biologika
Imutex
Inovio
Integrated Biotherapeutics
Johnson & Johnson/Janssen
GeneOne Life Science
GlaxoSmithKline
NewLink Genetics
Merck
Novartis
Novavax
Pfizer
Profectus BioSciences
Sanofi Pasteur
Takeda
Themis Biosciences
Tianjin CanSino Biotechnology
Vaccitech
Valneva

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1 Table of Concents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL Insight on Vaccines for Emerging Infectious Diseases

3. Overview of Emerging Infectious Diseases

3.1 Defining Emerging Infectious Diseases (EIDs)

3.2 Drivers of Emerging Infections & Routes of Transmission

3.3 Key EIDs

3.4 Ebola Virus Disease

3.5 Zika Virus Disease

3.6 Middle East Respiratory Syndrome (MERS) and Other EIDs

4. Clinical Trial Design

4.1 Clinical Trial Design Challenges

4.2 Randomization Units

4.3 Selection of Clinical Trial Population and Comparator

4.4 Additional Strategies for Vaccine Approvals

4.5 Unmet Needs in Clinical Trial Design

5. Vaccine Platform Technologies

5.1 Overview of Vaccine Platform Technologies

5.2 Vaccine Platforms By Stage of Development

5.3 Live-attenuated Vaccines

5.4 Viral Vector-Based Vaccines

5.5 DNA Vaccines

5.6 Whole-Inactivated Vaccines, Subunit Vaccines, and VLPs

6. Funding and Market Incentives

6.1 Funding Sources for Vaccines for EIDs

6.2 Push and Pull Incentives

6.3 Challenges for Funding of Vaccine Development

6.4 Lessons from the Ebola and Zika Outbreaks

7. Global Collaborations for Vaccine Development

7.1 Global Vaccine Development Fund and Priority Diseases

7.2 Coalition for Epidemic Preparedness Innovations (CEPI)

7.3 Vaccine Preparedness

7.4 Global Virome Project (GVP) and Other Public-Private Partnerships

8. Pipeline Vaccines for Key Emerging Infectious Diseases

8.1 Clinical Development of Vaccines for EIDs

8.2 Ebola Vaccine Pipeline

8.3 Zika Vaccine Pipeline

8.4 MERS-CoV Vaccine Pipeline

9. Surveillance and Healthcare Infrastructures

9.1 Disease Surveillance for EIDs

9.2 Logistical Challenges for Vaccine Delivery

9.3 Vaccine Preparedness

9.4 Unmet Needs in Basic Vaccine Research

10. Appendix

12.1 Sources

12.2 Methodology

12.3 Primary Research

12.4 About the Authors

12.5 About GlobalData

Frequently asked questions

Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies thematic reports
Currency USD
$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies in real time.

  • Access a live Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.